bluebird bio Inc. (BLUE)
| Bid | 4 |
| Market Cap | 48.67M |
| Revenue (ttm) | 103.95M |
| Net Income (ttm) | -199.98M |
| EPS (ttm) | -20.59 |
| PE Ratio (ttm) | -0.2413793103448276 |
| Forward PE | -0.58 |
| Analyst | Hold |
| Ask | 4.99 |
| Volume | 1,245,197 |
| Avg. Volume (20D) | 576,322 |
| Open | 4.97 |
| Previous Close | 4.97 |
| Day's Range | 4.97 - 4.97 |
| 52-Week Range | 3.20 - 28.60 |
| Beta | 0.36 |
About BLUE
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for BLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 months ago · newsfilecorp.com
Mines D'Or Orbec Announces Closing of Second and Final Tranche of Private PlacementBrossard, Quebec--(Newsfile Corp. - June 9, 2025) - Further to its news release dated April 24, 2025, Mines D'Or Orbec Inc. (TSXV: BLUE) ("Orbec" or the "Company") is pleased to announce that it has c...
2 months ago · businesswire.com
bluebird bio Announces Completion of Acquisition by Carlyle and SK CapitalSOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by gl...
2 months ago · businesswire.com
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender OfferWASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer comme...
3 months ago · businesswire.com
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender InstructionsSOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...